



Supplementary Figure 2. Prevalence of Visceral fat obesity (VFO), sarcopenia (defined by BMI- or height-adjusted SMA), and myosteatosis in non-obese controls and individuals with NAFLD. Asterisk (*) denotes comparison between controls and NAFLD without obesity (** $P < 0.001$ and * $P < 0.05$ by chi-squared test). NAFLD, non-alcoholic fatty liver disease; SMA, skeletal muscle area; BMI, body mass index.